HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria
- 1 March 2020
- journal article
- research article
- Published by Elsevier in European Urology Focus
- Vol. 6 (2) , 284-291
Abstract
No abstract availableKeywords
Funding Information
- Shanghai Shen Kang Hospital Development Center (16CR2003A)
This publication has 19 references indexed in Scilit:
- Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder CancerPLOS ONE, 2015
- A Noninvasive Multianalyte Urine-Based Diagnostic Assay for Urothelial Cancer of the Bladder in the Evaluation of HematuriaMayo Clinic Proceedings, 2012
- Genome-wide Analysis of CpG Island Methylation in Bladder Cancer Identified TBX2, TBX3, GATA2, and ZIC4 as pTa-Specific Prognostic MarkersEuropean Urology, 2012
- A methylation assay for the detection of non‐muscle‐invasive bladder cancer (NMIBC) recurrences in voided urineBJU International, 2011
- Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urineBMC Medical Genomics, 2011
- Cancer epigenetics reaches mainstream oncologyNature Medicine, 2011
- Epigenetics in CancerNew England Journal of Medicine, 2008
- Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy—part I: definition, detection, prevalence, and etiologyUrology, 2001
- Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy—part II: patient evaluation, cytology, voided markers, imaging, cystoscopy, nephrology evaluation, and follow-upUrology, 2001
- A PROSPECTIVE ANALYSIS OF 1,930 PATIENTS WITH HEMATURIA TO EVALUATE CURRENT DIAGNOSTIC PRACTICEJournal of Urology, 2000